SaRNA


Small activating RNAs are small double-stranded RNAs that target gene promoters to induce transcriptional gene activation in a process known as RNA activation.
Small dsRNAs, such as small interfering RNAs and microRNAs, are known to be the trigger of an evolutionarily conserved mechanism known as RNA interference. RNAi invariably leads to gene silencing via remodeling of chromatin to thereby suppress transcription, degrading complementary mRNA, or blocking protein translation. Later it was found that dsRNAs can also act to activate transcription and was thus designated saRNA. By targeting selected sequences in gene promoters, saRNAs induce target gene expression at the transcriptional/epigenetic level.
saRNAs are typically 21 nucleotides in length with 2 nucleotides overhang at the 3' end of each strand, the same structure as a typical siRNA. To identify an saRNA that can activate a gene of interest, several saRNAs need to be designed within a 1- to 2-kb promoter region by following a set of rules and tested in cultured cells. In some reports, saRNAs are designed in such a way to target non-coding transcripts that overlap the promoter sequence of a protein coding gene. Both chemically synthesized saRNAs and saRNAs expressed as short hairpin RNA have been used in in vitro and in vivo experiments.
Therapeutic use of saRNAs has been tested in animal models to treat cancer, liver disease, ischemia, and erectile dysfunction. A detailed online resource for small activating RNAs for upregulation of the genes is developed by Dar et al. in 2018 and published in the Journal of Molecular Biology.
In 2016, a phase I clinical trial was launched for the saRNA drug MTL-CEBPA, the first of its kind, to treat liver cancer.